Valuation: Amarin Corporation plc

Market Cap 255M 229M 210M 190M 356M 24.23B 363M 2.51B 1.01B 12.75B 958M 937M 40.2B P/E 2026 *
-303x
P/E 2027 * -202x
Enterprise Value 83.5M 74.78M 68.79M 62.33M 117M 7.93B 119M 820M 329M 4.17B 313M 307M 13.15B EV / Sales 2026 *
0.5x
EV / Sales 2027 * 0.39x
Free-Float
86.93%
Yield 2026 *
-
Yield 2027 * -
1 day-4.91%
1 week+2.71%
Current month-6.85%
1 month-6.85%
3 months-14.90%
6 months-13.07%
Current year-13.22%
1 week 11.7
Extreme 11.7
13.18
1 month 11.25
Extreme 11.25
13.18
Current year 11.25
Extreme 11.25
17.31
1 year 11.25
Extreme 11.25
17.31
3 years 7.08
Extreme 7.08
27.4
5 years 7.08
Extreme 7.08
97.8
10 years 7.08
Extreme 7.08
522.4
Manager TitleAgeSince
Chief Executive Officer 63 04/06/2024
Director of Finance/CFO 42 23/10/2024
Compliance Officer 56 15/11/2023
Director TitleAgeSince
Director/Board Member 63 04/06/2024
Director/Board Member 43 28/02/2023
Director/Board Member 67 28/02/2023
Date Insider Type Main position Quantity % Market Cap. Importance
1/8/26 Exercice

Chief Financial Officer

781 0.0002%
1/7/26 Exercice

Chief Operating Officer

9,302 0.0022%
1/7/26 Exercice

Chief Technology Officer

9,263 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
-4.91%+2.71% - - 255M
Average -4.91%
Weighted average by Cap. -4.91%

Financials

2026 *2027 *
Net sales 166M 149M 137M 124M 232M 15.77B 236M 1.63B 655M 8.3B 623M 610M 26.16B 176M 158M 145M 131M 246M 16.72B 250M 1.73B 695M 8.8B 661M 647M 27.74B
Net income -23.57M -21.11M -19.42M -17.59M -32.88M -2.24B -33.5M -232M -92.94M -1.18B -88.45M -86.57M -3.71B -13.16M -11.78M -10.84M -9.82M -18.36M -1.25B -18.7M -129M -51.89M -657M -49.38M -48.33M -2.07B
Net Debt -172M -154M -141M -128M -240M -16.3B -244M -1.69B -677M -8.58B -644M -631M -27.04B -187M -167M -154M -140M -261M -17.75B -266M -1.84B -737M -9.34B -701M -687M -29.44B
Projected Income Statement - Annual - Amarin Corporation plc
Logo Amarin Corporation plc
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Employees
80
Date Price Change Volume
30/10/26 USD 12.11 -4.91% 101,277
29/10/26 USD 12.74 -0.08% 40,038
28/10/26 USD 12.75 +6.65% 161,302
27/10/26 USD 11.95 -1.16% 56,894
26/10/26 USD 12.09 +2.54% 64,818
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Amarin Corporation plc
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
2
Last Close Price
12.11USD
Average target price
12.50USD
Spread / Average Target
+3.22%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amarin Corporation plc
  1. Stock Market
  2. Stocks
  3. AMRN Stock